IN THE CLAIMS

1. (currently amended) A method of treating a disease related to a pre-messenger RNA splicing process within a cell comprising administering to a patient in need thereof $\frac{1}{2}$ of $\frac{1}{2}$ indole-derived compounds such as a medicine comprising a compound of $\frac{1}{2}$ derivatives of benzo-indole or pyrido-indole $\frac{1}{2}$ derivative corresponding to the following formula I:

Formula I

or a pharmaceutically

acceptable salt, isomer and/or mixture thereof, wherein

when ring A is in position b:

X represents N or CR4 or N^+R4 anhydro base, and eyele-ring A, which is in position b corresponds to

$$\begin{array}{c|cccc}
R1 & & & & & & \\
\hline
N & & & & & & \\
\hline
\text{or} & & & & & \\
\end{array}$$

<u>,- or</u>

when cycle A is in position a or c:

X represents N,

_____and_<u>cycle_ring</u>A, which is in position a or c_corresponds to



in whichwherein: R1 represents:

 $\tilde{-}$ an atom of hydrogen or halogen or a -C=N-OH or -O-C(=O)(CH₃) or -C=N group, or

-a - N - R6R7 group,

where wherein R6 and R7 represent independently of one another÷

~a hydrogen atom,

—a <u>saturated</u> or <u>unsaturated</u> ring <u>at having C6</u>, <u>saturated or unsaturated</u>, <u>possibly optionally</u> containing an atom of nitrogen and possibly substituted by one or more alkyl groups at C1 to C3, or

-a linear, branched and/or unsaturated alkyl group at having Cl to Cl3 in which one or more atoms of carbon can be is optionally substituted by an atom of nitrogen, the aforementioned said alkyl group being possibly optionally substituted by one or more -OH and/or =O groups and/or by a group such asselected from the following comopunds:

the aforementionedsaid group being possibly optionally substituted by an alkyl group at C1 to C3 which itself is possibly substituted by an amino group, or —a -NH-R8 group

where $\underline{\text{in}}$ R8 represents an alkyl-N-R9R10 group $\underline{\prime}$

where wherein the alkyl group of said alkyl-N-R9R10 group represents a linear or branched group at having C1 to C13 possibly optionally unsaturated and/or substituted by one or more alkyl groups at C1 to C3 and/or hydroxyl groups, and

R9 and R10 represent independently of one another a hydrogen atom or an alkyl group at having C1 to C4 possibly optionally substituted by one or more hydroxyl and/or oxo groups,

R2 represents a hydrogen atom, a methyl group or a $-NH-(CH_2)_3-N(CH_3)_2$ group, or R2 is absent when said ring A is in position a,

R3 represents a hydrogen atom, a halogen atom or a methyl, amino or methoxymethyl group, or said -NH-R8 such as defined previouslygroup,

R4 represents a hydrogen atom, a hydroxyl or alkyl group at having C1-C6 or a methoxy group possibly optionally substituted by a phenyl group,

R5 represents a hydrogen atom or a methyl or methoxymethyl group when X represents N or CR4 $\underline{\text{or}}_{\text{and}}$ R5 is absent when X represents N+R4 anhydro base,


Z represents a hydrogen atom or a hydroxyl or methoxy group or -0-alkyl-C=O(O-alkyl), with alkyl representing a group $at-\underline{having}$ C1-C6,

R11 and R12 represent independently of one another a hydrogen atom or an alkyl group at having C1-C3, and or R11 is absent when said ring A is in position c, and

R13 represents a hydrogen atom or a methyl group, and the pharmaceutically acceptable salts of the aforementioned compounds, their isomers and/or mixtures,

for the preparation of a medication for the treatment of diseases related to pre-messenger RNA splicing processes within the cell.

2. (currently amended) Use—The method according toof claim 1, wherein the said compound of benzo-indole derivatives are is a pyrido-carbazole derivatives of said, and in formula I, when wherein X represents CR4, and ring A represents



wherein R1 represents a said -N-R6R7 or said -NH-R8 group, a hydrogen atom, a

a -C=N-OH or -O-C (=O) (CH₃) or $-C\equiv N$ group,

R3 represents a hydrogen atom,

R4 represents a hydroxy group or a methoxy group possibly optionally substituted by a phenyl group, and

R13 represents a hydrogen atom, and

R2, R5, R6, R7, R8, R9, R10, R11 and R12 are such as defined in claim 1.

3. (currently amended) The method of Use according to claim 1, wherein the said compound of pyrido-indole derivatives are is a derivatives of pyrido-pyrrolo-isoquinoline, and in of said formula I, when wherein X represents N or N*R4 anhydro base, and ring A represents

wherein R1 represents a halogen atom, an amino group, said -N-R6R7 or said -NH-R8 group,

- R2 represents a hydrogen atom or a methyl group,
- R3 represents a hydrogen atom or a-said NH-R8 group,
- R4 represents a hydrogen atom or a methyl group,
- R5 represents a hydrogen atom or a methyl group when X represents N $\underline{\text{orand}}$ R5 is absent when X represents $\underline{\text{said}}$ N⁺R4 anhydro base, and

R11 represents a hydrogen atom or a methyl group, and R6, R7, R8, R9, R10, R12 and R13 are such as defined in claim 1.

4. (currently amended) Use according to The method of claim 1, wherein the said pyrido-indole derivatives are a derivatives of benzo-pyrido-indole, and in of said formula I, when wherein X represents N, and ring A represents



and is in position a, b or c,

R3 represents a halogen atom, an amino group, $\frac{\text{a}-\text{said}}{\text{-N-R6R7}}$ or $\frac{\text{said}}{\text{-NH-R8}}$ group,

R5 represents a hydrogen atom or a methyl group,

R2 and R11 represent independently of one another —a hydrogen atom or a methyl group, or are respectively absent when ring A is in position a and c, and

R13 represents a hydrogen atom, and

Z, R6, R7, R8, R9, R10 and R12 are such as defined in claim 1.

- 5. (currently amended) The method of Use according to claim 1, wherein the said compound is selected from the a group comprised consisting of:
- $\tilde{-}$ N'-(9-methoxy-5,6,11-trimethyl-6H-pyrido[4,3-b]carbazol-1-yl)-N,N-dimethyl-propane-1,3-diamine,
- $\tilde{-}$ N'-(9-methoxy-6,11-dimethyl-6H-pyrido[4,3-b]carbazol-1-yl)-N,N-dimethyl-propane-1,3-diamine,
- -10-chloro-2, 6-dimethyl-2H-pyrido[3',4':4,5]pyrrolo[2,3-

g]isoquinoline, $\tilde{-}9$ -hydroxy-5-methyl-6H-pyrido[4,3-b]carbazol-1-yl acetic acid $\tilde{-}1$ -(3-dimethylamino-propylamino)5-methyl-6H-pyrido[4,3blcarbazol-9-ol, -9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1-carbaldehyde oxime, $\tilde{-}$ N'(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-11-yl)-N,Ndimethyl-propane-1,3-diamine, $\tilde{-}$ N, N-diethyl-N'-(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1yl)-propane-1,3-diamine, $\tilde{-}$ N'-(6,11-dimethyl-5H-pyrido[3',4':4,5]pyrrolo[2,3g]isoquinolin-10-yl)-N, N-dimethyl-propane-1, 3-diamine, \tilde{a} allyl-(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-1-yl)amine, $\tilde{-}$ N, N-diethyl-N4-(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1yl)-pentane-1,4-diamine, $\tilde{-}$ N, N-dimethyl-N'-(6-methyl-5H-pyrido[3',4':4,5]pyrrolo[2,3q]isoquinolin-10-yl)-propane-1,3-diamine, $\tilde{-}9$ -methoxy-1-[6-(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1ylamino) -hexylamino] -2,5-dimethyl-6H-pyrido[4,3-b]carbazol-2-ium iodide, $-\{3-[4(3-amino-propyl)-piperazin-1-yl]-propyl\}-9-methoxy-5$ methyl-6H-pyrido[4,3-b]carbazol-1-yl)-amine, $\tilde{-}$ (3-imidazol-1-yl-propyl)-9-methoxy-5-methyl-6H-pyrido[4,3b]carbazol-1-yl)-amine, $\tilde{-}$ (9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1-yl)-(2,2,6,6tetramethyl-piperidin-4-yl)-amine, -N-ethyl-N-[3-(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-1-ylamino)-propyl]-succinamic acid, \tilde{N} -ethyl-N-[3-(6-methyl-5H-pyrido[3',4':4,5]pyrrolo[2,3g]isoquinolin-10-ylamino)-propyl]-succinamic acid, $|\tilde{-5}, 11-dimethyl-1-(3-methyl-butylamino)-6H-pyrido[4,3-b]carbazol-$ 9-ol, $\tilde{-}2$ -{(2-hydroxy-ethyl)-[3-(6-methyl-5Hpyrido[3',4',:4,5]pyrrolo[2,3-g]isoquinolin-10-ylamino} propyl]amino-ethanol,

```
\tilde{-}N, N-diethyl-N'-(6-methyl-5H-pyrido[3',4':4,5]pyrrolo[2,3-
 glisoquinolin-10-yl)-ethane-1,2-diamine,
\tilde{-}N'-(9-benzyloxy-6-methoxymethyl-5-methyl-6H-pyrido[4,3-
 b]carbazol-1-yl)-N, N-diethyl-propane-1, 3-diamine,
\tilde{-}1-(3-diethylamino-propylamino)-6-methoxymethyl-5-methyl-6H-
 pyrido[4,3-b]carbazol-9-ol,
 \tilde{-}9-methoxy-5-methyl-4,6-dihydro-3H-pyrido[4,3-b]carbazol,
-N-(6-methyl-5H-pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolin-10-
 yl)-propane-1,3-diamine,
\tilde{-}1-(3-diethylamino-propylamino)-5,11-dimethyl-6H-pyrido[4,3-
 b]carbazol-9-ol,
-N-(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-1-yl)-
 propane-1, 3-diamine,
-N-3-(5,6-dimethyl-5H-pyrido[3',4':4,5]pyrrolo[2,3-
 g]isoquinolin-10-yl)-N, N-1-diethyl-butane-1,3-diamine,
\tilde{-}N, N-diethyl-N'-(9-methoxy-5,6,11-trimethyl-6H-pyrido[4,3-
 b]carbazol-1-yl)-ethane-1,2-diamine,
\tilde{-}N-(6,11-dimethyl-5H-pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolin-
 10-yl)-N'-ethyl-propane-1,3-diamine,
\tilde{-}N-(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1-yl)-propane-
 1,3-diamine,
\tilde{-}N'-(5,6-dimethyl-5H-pyrido[3'4':4,5]pyrrolo[2,3-g]isoquinolin-
 10-yl)-N, N-dimethyl-propane-1, 3-diamine,
-N-(5,6-dimethyl-5H-pyrido[3'4':4,5]pyrrolo[2,3-g]isoquinolin-
 10-yl)-N'-ethyl-propane-1,3-diamine,
 \tilde{-}9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1-carbonitrile,
-1-(3-diethylamino-propylamino)-5-methyl-6H-pyrido[4,3-
 b]carbazol-9-ol.
\tilde{-}(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-1-yl)-(3-
 morpholin-4-yl-propyl)-amine,
\tilde{-}N-ethyl-N'-(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1-yl)-
 propane-1, 3-diamine,
\tilde{-}N-(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1-yl)-pentane-
 1,5-diamine,
\tilde{N}-(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1-yl)-hexane-
 1,6-diamine,
-N'-(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1-yl)-N,N-
```

```
dimethyl-ethane-1,2-diamine,
\tilde{-}N, N-diethyl-N'-(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-
 b]carbazol-1-yl)-propane-1,3-diamine,
\tilde{-}(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1-yl)-(2-
 pyrrolidin-1-yl-ethyl)-amine,
\tilde{-3}-(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1-ylamino)-
 propane-1,2-diol,
\tilde{-1}-diethylamino-3-(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-
 1-ylamino)-propan-2-ol,
\tilde{-}(3-imidazol-1-yl-propyl)-(6-methyl-5H-
 pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolin-10-yl)-amine,
-\frac{1}{2}decyl-(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-1-yl)-
 \tilde{-}N-(3-methoxy-10-methyl-11H-benzo[g]pyrido[4,3-b]indol-7-yl)-
 butane-1, 4-diamine,
-8-methyl-11-(3-methylamino-propylammo)-7H-benzo[e]pyrido[4,3-
 b]indol-3-ol,
\tilde{-1}-diethylamino-3-(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-
 b]carbazol-1-ylamino)-propan-2-ol,
\tilde{-}N, N-diethyl-N'-(9-methoxy-5,6-dimethyl-6H-pyrido[4,3-
 b]carbazol-1-yl)-ethane-1,2-diamine,
\tilde{-}N-N, diethyl-N'-(6-methyl-5H-pyrido[3',4':4,5]pyrrolo[2,3-
 g]isoquinolin-10-yl)-propane-1,3-diamine,
\tilde{-}N-1,N-10-Bis-(3-diethylamino-propyl)-3,6-dimethyl-5H-
 pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinoline-1,10-diamine,
\tilde{-}N-ethyl-N'-(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-1-
 vl)-propane-1,3-diamine,
\tilde{-}N-(5,6-dimethyl-5H-benzo[f]pyrido(4,3]indol-1-yl)-N'-ethyl-
 propane-1, 3-diamine,
-N' - (9 - methoxy - 5, 6 - dimethyl - 5H - benzo[f]pyrido[4, 3 - b]indol - 1 - yl) -
 N, N-dimethyl-propane-1, 3-diamine,
\tilde{-1}-(3-dimethylamino-propylamino)-5,6-dimethyl-5H-
 benzo[f]pyrido[4,3-b]indol-9-ol,
-N-(3-methoxy-8-methyl-7H-benzo[e]pyrido[4,3-b]indol-11-yl)-N'-
 methyl-propane-1, 3-diamine,
 \tilde{-5}-(7-chloro-10-methyl-11H-benzo[g]pyrido[4,3-b]indol-3-yloxy)-
 pentanoic acid ethyl ester,
```

```
-N, N-dimethyl-N'-(10, 11-dimethyl-10H-
 pyrido[3'4':4,5]pyrrolo[3,2-q]quinoline)4-yl-propane-1,3-
 diamine,
\tilde{-}N, N-diethyl-N'-(10,11-dimethyl-10H-pyrido[3'4':4,5]pyrrolo[3,2-
 ]quinoline)-4-yl-propane-1,3-diamine,
\tilde{-}N'-(7-methoxy-10,11-dimethyl-10H-pyrido[2,3-b]carbazol-4-yl)-
 N, N-dimethyl-propane-1, 3-diamine,
\tilde{-}N, N-diethyl-N'-(7-methoxy-10,11-dimethyl-10H-pyrido[2,3-
 b]carbazol-4-yl)-propane-1,3-diamine,
 \tilde{-}9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-1-yl-amine,
\tilde{-}N, N-diethyl-N'-(7-methoxy-11-methyl-10H-pyrido[2,3-b]carbazol-
 4-yl)-propane-1,3-diamine,
\tilde{-}N, N-diethyl-N'-(11-methyl-10H-pyrido[3',4':4,5]pyrrolo[3,2-
 g]quinoline)-4-yl-propane-1,3-diamine,
\tilde{-}N, N-diethyl-N'-(7-methoxy-5,11-dimethyl-10H-pyrido[2,3-
 b]carbazol-4yl)-propane-1,3-diamine,
\tilde{-}N, N-dimethyl-N'-(11-methyl-10H-pyrido[3',4':4,5]pyrrolo[3,2-
 g]quinoline)-4-yl-propane-1,3-diamine,
\tilde{-11}-(3-dimethylamino-propylamino)-8-ethyl-7H-benzo[e]pyrido[4,3-
 b]indol-3-ol,
\tilde{-7}-(3-diethylamino-propylamino)10,11-dimethyl-11H-
 benzo[g]pyrido[4,3-b]indol-4-ol,
\tilde{-}11-(3-dimethylamino-propylamine)-7H-benzo[e]pyrido[4,3-b]indol-
 3-01,
-N'-(3-methoxy-7H-benzo[e]pyrido[4,3-b]indol-11-yl)-N,N-
 dimethyl-propane-1,3-diamine,
\tilde{-}N'-8-ethyl-3-methoxy-7-methyl-7H-benzo[e]pyrido[4,3-b]indol-11-
 yl)-N, N-dimethyl-propane-1, 3-diamine,
-11-(3-dimethylamino-propylamino)-8-methyl-7H-
 benzo[e]pyrido[4,3-b]indol-2-ol,
\tilde{-}N, N-diethyl-N'-(3-methoxy-10, 11-dimethyl-11H-
 benzo[q]pyrido[4,3-b]indol-7-yl)-propane-1,3-diamine,
\tilde{-11}-(3-dimethylamino-propylamino)-7,8-dimethyl-7H-
 benzo[e]pyrido[4,3-b]indol-3-ol,
\tilde{-7}-(3-dimethylamino-propylamino)-10-methyl-11H-
 benzo[g]pyrido[4,3-b]indol-4-ol,
-N'-(2-methoxy-8-methyl-7H-benzo[e]pyrido[4,3-b]indol-11-yl)-
```

N, N-dimethyl-propane-1, 3-diamine, -N'-(10,11-dimethyl-11H-benzo[q]pyrido[4,3-b]indol-7-yl)-N,Ndiethyl-propane-1,3-diamine, -N'-(7,8-dimethyl-7H-benzo[e]pyrido[4,3-b]indol-11-yl)-N,Ndimethyl-propane-1,3-diamine, $\tilde{-}$ N,N-dimethyl-N'-(10-methyl-11H-benzo[q]pyrido[4,3-b]indol-7yl)-propane-1,3-diamine, $\tilde{-7}$ -(3-diethylamino-propylamino)-10,11-dimethyl-11Hbenzo[g]pyrido[4,3-b]indol-3-ol, $\tilde{-}$ N, N-diethyl-N'-(10-methyl-11H-benzo[g]pyrido[4,3-b]indol-7-yl)propane-1,3-diamine, -4-methoxy-10-methyl-11H-benzo[g]pyrido[4,3-b]indol-7-ylamine, $\tilde{-}$ N, N-diethyl-N'-(3-methoxy-10-methyl-11H-benzo[g]pyrido[4,3b]indol-7-yl)-propane-1,3-diamine, $\tilde{N}' - (4 - \text{methoxy} - 10, 11 - \text{dimethyl} - 11 + \text{benzo}[q] \text{pyrido}[4, 3 - b] \text{ indol} - 7 - \frac{1}{2}$ yl)-N, N-dimethyl-propane-1, 3-diamine, -7-(3-(dimethylamino-propylamino)-10,11-dimethyl-11Hbenzo[q]pyrido[4,3-b]indol-4-ol, -N, N-dimethyl-N'-(8-methyl-7H-benzo[e]pyrido[4,3-b]indol-11-yl)propane-1, 3-diamine, $\tilde{-}11$ -(3-dimethylamino-2-methyl-propylamino)-8-methyl-7Hbenzo[e]pyrido[4,3-b]indol-3-ol, \tilde{N} -(3-methoxy-8-methyl-7H-benzo[e]pyrido[4,3-b]indol-11-yl)propane-1, 3-diamine, $\tilde{-}11$ -(3-amino-propylamino)-8-methyl-7H-benzo[e]pyrido[4,3blindol-3-ol, \tilde{N} -(3-methoxy-10-methyl-11H-benzo[g]pyrido[4,3-b]indol-7-yl)propane-1, 3-diamine, -N'-(3-methoxy-8-methyl-7H-benzo[e]pyrido[4,3-b]indol-11-yl)-N, N-dimethyl-propane-1, 3-diamine, $\tilde{N}' - (4 - \text{methoxy} - 8 - \text{methyl} - 7 + \text{methozo}[e] \text{pyrido}[4, 3 - b] \text{ indol} - 11 - yl) - yl$ N, N-dimethyl-propane-1, 3-diamine, $\tilde{-}$ N-(3-amino-propyl)N'-[3-(3-methoxy-8-methyl-7Hbenzo[e]pyrido[4,3-b]indol-11-ylamino)-propyl]butane-1,4diamine, $\tilde{-}$ N-(3-methoxy-8-methyl-7H-benzo[e]pyrido[4,3-b]indol-11-yl)hexane-1, 6-diamine,

amine.

- ~N-[3-(3-methoxy-10-methyl-11H-benzo[g]pyrido[4,3-b]indol-7-ylamino)-propyl]-propane-1,3-diamine,
 ~N-[3-(3-methoxy-10-methyl-11H-benzo[g]pyrido[4,3-b]indol-7-ylamino)-propyl]-N-methyl-propane-1,3-diamine,
 ~N-[3-(3-methoxy-8-methyl-7H-benzo[e]pyrido[4,3-b]indol-11-ylamino)-propyl]-propane-1,3-diamine,
 ~N-(5,6-dimethyl-5H-pyrido[3'4':4,5]pyrrolo[2,3-g]isoquinolin-10-yl)-N'-ethyl-propane-1,3-diamine,_and
 ~6-methyl-5H-pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolin-10-yl-
 - 6. (currently amended) Use according to The method as in claims 1 and or 2, wherein the said compound is selected from the a group comprised consisting of:
 - $\tilde{-}$ N'-(9-methoxy-5,6,11-trimethyl-6H-pyrido[4,3-b]carbazol-1-yl)-N,N-dimethyl-propane-1,3-diamine,
- -N'-(9-methoxy-6,11-dimethyl-5H-pyrido[4,3-b]carbazol-1-yl)-N,N-dimethyl-propane-1,3-diamine,
- -9-hydroxy-5-methyl-6H-pyrido[4,3-b]carbazol-1-yl acetic acid ester,
- -1-(3-dimethylamino-propylamino)5-methyl-6H-pyrido[4,3-b]carbazol-9-ol,
- $\tilde{-}9$ -methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1-carbaldehyde oxime,
- -N'(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-11-yl)-N,N-dimethyl-propane-1,3-diamine,
- $\tilde{-}$ N, N-diethyl-N'-(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1-yl)-propane-1,3-diamine,
- \tilde{a} allyl-(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-1-yl)-amine,
- $\tilde{-}$ N, N-diethyl-N4-(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1-yl)-pentane-1,4-diamine,
- $\tilde{-}9$ -methoxy-1-[6-(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1-ylamino)-hexylamino]-2,5-dimethyl-6H-pyrido[4,3-b]carbazol-2-iumiodide,
- $-\{3-[4(3-amino-propy1)-piperazin-1-y1]-propy1\}-9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1-yl)-amine,$

```
\tilde{-}(3-imidazol-1-yl-propyl)-9-methoxy-5-methyl-6H-pyrido[4,3-
 b]carbazol-1-yl)-amine,
\tilde{-}(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1-yl)-(2,2,6,6-
 tetramethyl-piperidin-4-yl)-amine,
\tilde{N}-ethyl-N-[3-(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-
 1-ylamino)-propyl]-succinamic acid,
-5, 11-dimethyl-1-(3-methyl-butylamino)-6H-pyrido[4,3-b]carbazol-
 9-01,
-N'-(9-benzyloxy-6-methoxymethyl-5-methyl-6H-pyrido[4,3-
 b]carbazol-1-yl)-N, N-diethyl-propane-1, 3-diamine,
-1-(3-diethylamino-propylamino)-6-methoxymethyl-5-methyl-6H-
 pyrido[4,3-b]carbazol-9-ol,
 \tilde{-}9-methoxy-5-methyl-4,6-dihydro-3H-pyrido[453-b]carbazol,
 \tilde{-}1-(3-diethylamino-propylamino)-5,11-dimethyl-6H-pyrido[4,3-
 b]carbazol-9-ol,
\tilde{N}-(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-1-yl)-
 propane-1,3-diamine,
\tilde{-}N, N-diethyl-N'-(9-methoxy-5, 6, 11-trimethyl-6H-pyrido[4, 3-
 b]carbazol-1-yl)-ethane-1,2-diamine,
\tilde{-}N-(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1-yl)-propane-
 1,3-diamine,
 \tilde{-}9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1-carbonitrile,
\tilde{-1}-(3-diethylamino-propylamino)-5-methyl-6H-pyrido[4,3-
 blcarbazol-9-ol,
\tilde{-}(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-1-yl)-(3-
 morpholin-4-yl-propyl)-amine,
\tilde{-}N-ethyl-N'-(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1-yl)-
 propane-1,3-diamine,
-N-(9-methoxy-5-methyl-6H-pyrido(4,3-b)carbazol-1-yl)-pentane-
 1,5-diamine
-N-(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1-yl)-hexane-
 1,6-diamine,
\tilde{-}N'-(9-\text{methoxy}-5-\text{methyl}-6H-\text{pyrido}[4,3-b]\text{carbazol}-1-yl)-N,N-
 dimethyl-ethane-1,2-diamine,
\tilde{-}N, N-diethyl-N'-(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-
 b]carbazol-1-yl)-propane-1,3-diamine,
\tilde{-}(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1-yl)-(2-
```

```
pyrrolidin-1-yl-ethyl)-amine,
\tilde{-3}-(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1-ylamino)-
 propane-1, 2-diol,
-1-diethylamino-3-(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-
 1-ylamino)-propan-2-ol,
-decyl-(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-1-yl)-
 amine,
-1-diethylamino-3-(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-
 b]carbazol-1-ylamino)-propan-2-ol,
\tilde{-}N, N-diethyl-N'-(9-methoxy-5,6-dimethyl-6H-pyrido[4,3-
 b]carbazol-1-yl)-ethane-1,2-diamine,
\tilde{-}N-ethyl-N'-(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-1-
 yl)-propane-1,3-diamine,
\tilde{-}N'-(7-methoxy-10,11-dimethyl-10H-pyrido[2,3-b]carbazol-4-yl)-
 N, N-dimethyl-propane-1, 3-diamine,
\tilde{-}N, N-diethyl-N'-(7-methoxy-10,11-dimethyl-10H-pyrido[2,3-
 b]carbazol-4-yl)-propane-1,3-diamine,
 \tilde{-}9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-1-yl-amine,
 \tilde{-}N, N-diethyl-N'-(7-methoxy-11-methyl-10H-pyrido[2,3-b]carbazol-
 4-yl)-propane-1,3-diamine, and
 \tilde{-}N, N-diethyl-N'-(7-methoxy-5, 11-dimethyl-10H-pyrido[2, 3-
 b]carbazol-4yl)-propane-1,3-diamine.
           7.
 claims 1 and or 4, wherein the said compound is selected from
 the a group comprised consisting of:
 \tilde{-}10-chloro-2,6-dimethyl-2H-pyrido[3',4':4,5]pyrrolo[2,3-
 alisoquinoline,
-N'-(6,11-dimethyl-5H-pyrido[3',4':4,5]pyrrolo[2,3-
 glisoquinolin-10-yl)-N, N-dimethyl-propane-1, 3-diamine,
\tilde{-}N, N-dimethyl-N'-(6-methyl-5H-pyrido[3',4':4,5]pyrrolo[2,3-
 q]isoquinolin-10-yl)-propane-1,3-diamine,
\tilde{-}N-ethyl-N-[3-(6-methyl-5H-pyrido[3',4':4,5]pyrrolo[2,3-
 g]isoquinolin-10-ylamino)-propyl]-succinamic acid,
\tilde{-2}-{(2-hydroxy-ethyl)-[3-(6-methyl-5H-
 pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolin-10-ylamino}propyl]-
 amino-ethanol,
```

```
\tilde{-}N, N-diethyl-N'-(6-methyl-5H-pyrido[3',4':4,5]pyrrolo[2,3-
 g]isoquinolin-10-yl)-ethane-1,2-diamine,
\tilde{N}-(6-methyl-5H-pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolin-10-
 yl)-propane-1,3-diamine,
\tilde{-}N-3-(5,6-dimethyl-5H-pyrido[3',4':4,5]pyrrolo[2,3-
 glisoquinolin-10-yl)-N, N-1-diethyl-butane-1,3-diamine,
\tilde{-}N-(6,11-dimethyl-5H-pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolin-
 10-yl)-N'-ethyl-propane-1,3-diamine,
\tilde{-}N'-(5)6-dimethyl-5H-pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolin-
 10-yl)-N, N-dimethyl-propane-1, 3-diamine,
\tilde{-}N-(5,6-dimethyl-5H-pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolin-
 10-yl)-N'-ethyl-propane-1,3-diamine,
\tilde{-}(3-imidazol-1-yl-propyl)-(6-methyl-5H-
 pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolin-10-yl)-amine,
\tilde{-}N-N-diethyl-N'-(6-methyl-5H-pyrido[3',4':4,5]pyrrolo[2,3-
 g]isoquinolin-10-yl)-propane-1,3-diamine,
|\tilde{-}N-1,N-10-Bis-(3-diethylamino-propyl)-3,6-dimethyl-5H-
 pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinoline-1,10-diamine,
\tilde{-}N, N-dimethyl-N'-(10,11-dimethyl-10H-
 pyrido[3'4':4,5]pyrrolo[3,2-q]quinoline)4-yl-propane-1,3-
 diamine,
-N, N-diethyl-N'-(10,11-dimethyl-10H-pyrido[3'4':4,5]pyrrolo[3,2-
 ]quinoline)-4-yl-propane-1,3-diamine,
-N, N-diethyl-N'-(11-methyl-10H-pyrido[3',4':4,5]pyrrolo[3,2-
 g]quinoline)-4-yl-propane-1,3-diamine,
\tilde{N}, N-dimethyl-N'-(11-methyl-10H-pyrido[3', 4':4,5]pyrrolo[3,2-
 g]quinoline)-4-yl-propane-1,3-diamine,
 \tilde{-}N-(5,6-dimethyl-5H-pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolin-
 10-yl)-N'-ethyl-propane-1,3-diamine, and
 \tilde{-}6-methyl-5H-pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolin-10-yl-
 amine.
```

8. (currently amended) Use according to The method as in claims 1 and or 5, wherein the said compound is selected from athe group constituted by consisting of:
--N-(3-methoxy-10-methyl-11H-benzo[g]pyrido[4,3-b]indol-7-yl)-butane-1,4-diamine,

```
-8-methyl-11-(3-methylamino-propylamino)-7H-benzo[e]pyrido[4,3-
 b]indol-3-ol,
\tilde{N}-(5,6-dimethyl-5H-benzo[f]pyrido[4,3]indol-1-yl)-N'-ethyl-
 propane-1, 3-diamine,
|\tilde{-}N'-(9-methoxy-5,6-dimethyl-5H-benzo[f]pyrido[4,3-b]indol-1-yl)-
 N, N-dimethyl-propane-1, 3-diamine,
-1-(3-dimethylamino-propylamino)-5,6-dimethyl-5H-
 benzo[f]pyrido[4,3-b]indol-9-ol,
-N-(3-methoxy-8-methyl-7H-benzo[e]pyrido[4,3-b]indol-11-yl)-N'-
 methyl-propane-1, 3-diamine,
\tilde{-5}-(7-chloro-10-methyl-11H-benzo[g]pyrido[4,3-b]indol-3-yloxy)-
 pentanoic acid ethyl ester,
\tilde{-}11-(3-\text{dimethylamino-propylamino})-8-\text{ethyl}-7\text{H-benzo}[e]pyrido[4,3-
 b]indol-3-ol,
\tilde{-7}-(3-diethylamino-propylamino)10,11-dimethyl-11H-
 benzo[q]pyrido[4,3-b]indol-4-ol,
-11-(3-dimethylamino-propylamine)-7H-benzo[e]pyrido[4,3-b]indol-
\tilde{N}' - (3-\text{methoxy} - 7H-\text{benzo}[e] \text{pyrido}[4, 3-b] \text{ indol} - 11-yl) - N, N-
 dimethyl-propane-1,3-diamine,
-N'-8-ethyl-3-methoxy-7-methyl-7H-benzo[e]pyrido[4,3-b]indol-11-
 yl)-N, N-dimethyl-propane-1, 3-diamine,
\tilde{-}11-(3-dimethylamino-propylamino)-8-methyl-7H-
 benzo[e]pyrido[4,3-b]indol-2-ol,
\tilde{-}N,N-diethyl-N'-(3-methoxy-10,11-dimethyl-11H-
 benzo[g]pyrido[4,3-b]indol-7-yl)-propane-1,3-diamine,
-11-(3-\text{dimethylamino-propylamino})-7,8-\text{dimethyl}-7H-
 benzo[e]pyrido[4,3-b]indol-3-ol,
\tilde{-7}-(3-dimethylamino-propylamino)-10-methyl-11H-
 benzo[g]pyrido[4,3-b]indol-4-ol,
-N'-(2-methoxy-8-methyl-7H-benzo[e]pyrido[4,3-b]indol-11-yl)-
 N, N-dimethyl-propane-1, 3-diamine,
\tilde{-}N'-(10,11-dimethyl-11H-benzo[g]pyrido[4,3-b]indol-7-yl)-N,N-
 diethyl-propane-1, 3-diamine,
-N'-(7,8-dimethyl-7H-benzo[e]pyrido[4,3-b]indol-11-yl)-N,N-
 dimethyl-propane-1,3-diamine,
-N, N-dimethyl-N'-(10-methyl-11H-benzo[g]pyrido[4,3-b]indol-7-
```

yl)-propane-1,3-diamine, $\tilde{-}7$ -(3-diethylamino-propylamino)-10,11-dimethyl-11Hbenzo[g]pyrido[4,3-b]indol-3-ol, $\tilde{-}$ N, N-diethyl-N'-(10-methyl-11H-benzo[g]pyrido[4,3-b]indol-7-yl)propane-1,3-diamine, -4-methoxy-10-methyl-11H-benzo[g]pyrido[4,3-b]indol-7-ylamine, $\tilde{-}$ N, N-diethyl-N'-(3-methoxy-10-methyl-11H-benzo[g]pyrido[4,3b]indol-7-yl)-propane-1,3-diamine, -N'-(4-methoxy-10,11-dimethyl-11H-benzo[q]pyrido[4,3-b]indol-7yl)-N, N-dimethyl-propane-1, 3-diamine, $\tilde{-7}$ -(3-(dimethylamino-propylamino)-10,11-dimethyl-11Hbenzo[g]pyrido[4,3-b]indol-4-ol, $\tilde{-}$ N, N-dimethyl-N'-(8-methyl-7H-benzo[e]pyrido[4,3-b]indol-11-yl)propane-1, 3-diamine, $\tilde{-}11-(3-\text{dimethylamino}-2-\text{methyl-propylammo})-8-\text{methyl}-7H$ benzo[e]pyrido[4,3-b]indol-3-ol, $\tilde{-}$ N-(3-methoxy-8-methyl-7H-benzo[e]pyrido[4,3-b]indol-11-yl)propane-1, 3-diamine, $\tilde{-}11-(3-amino-propylamino)-8-methyl-7H-benzo[e]pyrido[4,3$ b]indol-3-ol, $\tilde{-}$ N-(3-methoxy-10-methyl-11H-benzo[g]pyrido[4,3-b]indol-7-yl)propane-1, 3-diamine, $\tilde{-}$ N'-(3-methoxy-8-methyl-7H-benzo[e]pyrido[4,3-b]indol-11-yl)-N, N-dimethyl-propane-1, 3-diamine, $\tilde{-}$ N'-(4-methoxy-8-methyl-7H-benzo[e]pyrido[4,3-b]indol-11-yl)-N, N-dimethyl-propane-1, 3-diamine, -N-(3-amino-propyl)N'-[3-(3-methoxy-8-methyl-7Hbenzo[e]pyrido[4,3-b]indol-11-ylamino)-propyl]butane-1,4diamine, -N-(3-methoxy-8-methyl-7H-benzo[e]pyrido[4,3-b]indol-11-yl)hexane-1,6-diamine, -N-[3-(3-methoxy-10-methyl-11H-benzo[q]pyrido[4,3-b]indol-7ylamino) -propyl] -propane-1, 3-diamine, $\tilde{-}$ N-[3-(3-methoxy-10-methyl-11H-benzo[g]pyrido[4,3-b]indol-7ylamino)-propyl]-N-methyl-propane-1,3-diamine, and $\tilde{-}$ N-[3-(3-methoxy-8-methyl-7H-benzo[e]pyrido[4,3-b]indol-11ylamino) -propyl] -propane-1, 3-diamine.

```
9.
            (currently amended) The method of claim 1<del>Use</del>
 according to any one of the preceding claims, wherein the said
 compound is selected from the a group comprised consisting of:
 -N'-(9-methoxy-5,6,11-trimethyl-6H-pyrido[4,3-b]carbazol-1-yl)-
 N, N-dimethyl-propane-1, 3-diamine,
 \tilde{-}N'-(9-methoxy-6,11-dimethyl-6H-pyrido[4,3-b]carbazol-1-yl)-N,N-
 dimethyl-propane-1,3-diamine,
-10-chloro-2,6-dimethyl-2H-pyrido[3',4':4,5]pyrrolo[2,3-
 q]isoquinoline,
-1-(3-dimethylamino-propylamino) 5-methyl-6H-pyrido[4,3-
 b]carbazol-9-ol,
\tilde{N}'(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-11-yl)-N,N-
 dimethyl-propane-1,3-diamine,
\tilde{a}allyl-(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-1-yl)-
 amine,
-N, N-diethyl-N4-(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1-
 vl)-pentane-1,4-diamine,
-9-methoxy-1-[6-(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1-
 ylamino) -hexylamino] -2,5-dimethyl-6H-pyrido[4,3-b] carbazol-2-ium
 iodide,
\tilde{-}(3-imidazol-1-yl-propyl)-9-methoxy-5-methyl-6H-pyrido[4,3-
 b]carbazol-1-yl)-amine,
\tilde{-}(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-1-yl)-(2,2,6,6-
 tetramethyl-piperidin-4-yl)-amine,
-N-ethyl-N-[3-(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-
 1-ylamino)-propyl]-succinamic acid,
\tilde{N}-ethyl-N-[3-(6-methyl-5H-pyrido[3',4':4,5]pyrrolo[2,3-
 glisoquinolin-10-ylamino)-propyl]-succinamic acid,
\tilde{-5}, 11-dimethyl-1-(3-methyl-butylamino)-6H-pyrido[4,3-b]carbazol-
 9-01,
\tilde{-}N,N-diethyl-N'-(6-methyl-5H-pyrido[3',4':4,5]pyrrolo[2,3-
 glisoquinolin-10-yl)-ethane-1,2-diamine,
~1-(3-diethylamino-propylamino)-5,11-dimethyl-6H-pyrido[4,3-
 b]carbazol-9-ol,
 \tilde{-}N, N-diethyl-N'-(9-methoxy-5, 6, 1-trimethyl-6H-pyrido[4, 3-
 b]carbazol-1-yl)-ethane-1,2-diamine,
```

```
-N'-(5,6-dimethyl-5H-pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolin-
 10-yl)-N, N-dimethyl-propane-1, 3-diamine,
-1-(3-\text{diethylamino-propylamino})-5-\text{methyl}-6\text{H-pyrido}[4,3-
 b]carbazol-9-ol,
\tilde{-}N, N-diethyl-N'-(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-
 b]carbazol-1-yl)-propane-1,3-diamine,
-1-diethylamino-3-(9-methoxy-5-methyl-6H-pyrido[4,3-b]carbazol-
 1-ylamino)-propan-2-ol,
-N-(3-methoxy-10-methyl-11H-benzo[q]pyrido[4,3-b]indol-7-yl)-
 butane-1, 4-diamine,
-N, N-diethyl-N'-(9-methoxy-5, 6-dimethyl-6H-pyrido[4, 3-
 b]carbazol-1-yl)-ethane-1,2-diamine,
\tilde{-}N, N-diethyl-N'-(6-methyl-5H-pyrido[3',4':4,5]pyrrolo[2,3-
 g]isoquinoline-10-yl)-propane-1,3-diamine,
\tilde{-}N-(3-methoxy-8-methyl-7H-benzo[e]pyrido[4,3-b]indol-11-yl)-N'-
 methyl-propane-1, 3-diamine,
 -4-methoxy-10-methyl-11H-benzo[g]pyrido[4,3-b]indol-7-ylamine,
-N-(3-methoxy-10-methyl-11H-benzo[g]pyrido[4,3-b]indol-7-yl)-
 propane-1, 3-diamine,
-N'-(3-methoxy-8-methyl-7H-benzo[e]pyrido[4,3-b]indol-11-yl)-
 N, N-dimethyl-propane-1, 3-diamine,
 \tilde{-}N-[3-(3-methoxy-10-methyl-11H-benzo[g]pyrido[4,3-b]indol-7-
 ylamino)-propyl]-N-methyl-propane-1,3-diamine, and
 -6-methyl-5H-pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolin-10-yl-
 amine.
```

- 10. (currently amended) Use according to The method of claim 1, wherein the said splicing processes are process is either constitutive or dependent on ESE, ISE, ESS or ISS regulatory sequences.
- 11. (currently amended) Use according to The method of claim 10, wherein the said splicing processes are process is either constitutive or dependent on ESE regulatory sequences.
- 12. (currently amended) Use according to The method of claim 1, wherein the said diseases related to the said splicing

process are—<u>is a genetic diseases resulting from splicing-process modification.</u> and are notably Frasier syndrome, frontotemporal dementia related to chromosome 17 (a form of Parkinson's), Leigh syndrome (a type of encephalopathy), atypical cystic fibrosis, certain—neuropathologies, such as in particular—Alzheimer's, related to Tau—protein—mutation, amyotrophy that influences the SMN (survival motor neuron)—gene, depression related to disturbances in serotonin splicing and certain cancers in which the overall splicing process is affected (notably breast cancer, colon cancer and certain lymphomas).

- 13. (currently amended) Use according to The method of claim 1, wherein the said diseases related to the said splicing process are is a diseases of viral origin for which ESE splicing sequences are identified.
- 14. (currently amended) Use according to The method of claim 13, wherein the said viral disease is AIDS.
- 15. (currently amended) Use according to claim 1 The method of claim 1, wherein said medicine also includes further comprises an excipient that makes it possible to formulate the compounds according to formula I.
- 16. (currently amended) Use according to The method of claim 15, wherein said medicine is presented in a solid or liquid form. to be prepared and administered by intravenous route.
- 17. (original) 10-chloro-2,6-dimethyl-2H-pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinoline.
- 18. (original) (9-methoxy-6-methyl-6H-pyrido[4,3-b]carbazol-1-yl)-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine.
 - 19. (original) N-ethyl-N-[3-(9-methoxy-5,11-dimethyl-6H-

pyrido[4,3-b]carbazol-1-ylamino)-propyl]-succinamic acid.

- 20. (original) N-ethyl-N-[3-(6-methyl-5H-pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolin-10-ylamino)-propyl]-succinamic acid.
- 21. (original) 9-methoxy-5-methyl-4,6-dihydro-3H-pyrido[4,3-b]carbazole.
- 22. (original) N-(3-amino-propyl)N'-[3-(3-methoxy-8-methyl-7H-benzo[e]pyrido[4,3-b]indol-11-ylamino)-propyl]butane-1,4-diamine.
- 23. (original) N-(3-methoxy-8-methyl-7H-benzo[e]pyrido[4,3-b]indol-11-yl)-hexane-1,6-diamine.
- 24. (original) N-[3-(3-methoxy-10-methyl-11H-benzo[g]pyrido[4,3-b]indol-7-ylamino)-propyl]-propane-1,3-diamine.
- 25. (original) N-[3-(3-methoxy-8-methyl-7H-benzo[e]pyrido[4,3-b]indol-11-ylamino)-propyl]-propane-1,3-diamine.
- 26. (currently amended) A medicine comprising a compound as in any one of claims 17 to 25. Compound according to any of claims 9 to 17 as a medicine.
- 27. (new) A medicine comprising any one of the compounds of claim 5.
- 28. (new) The method of claim 12, wherein said genetic disease is Frasier syndrome, frontotemporal dementia related to chromosome 17 (a form of Parkinson's), Leigh syndrome (a type of encephalopathy), atypical cystic fibrosis, a certain neuropathology related to Tau protein mutation, Alzheimer's disease, amyotrophy that influences the SMN (survival motor

Application No.: 10/570,849 Docket No.: REGIM 3.3-085

neuron) gene, depression related to disturbances in serotonin splicing or a certain cancer in which the overall splicing process is affected.

29. (new) The method of claim 34, wherein said cancer is breast cancer, colon cancer or certain lymphomas.